Orally disintegrating Zyprexa appears to cause less weight gain Carlat Reports

Orally disintegrating Zyprexa appears to cause less weight gain

The Carlat Psychiatry Report, Volume 6, Number 5, May 2008
https://www.thecarlatreport.com/newsletter-issue/tcprv6n5/

From The Carlat Psychiatry Report, May 2008, Neuropsychological Testing

Issue Links: Learning Objectives | Editorial Information

Dilip Jeste, MD

A few studies have shown that orally disintegrating Zyprexa Zydis appears to cause less weight gain than standard Zyprexa, but they have been short term studies.

You can't view details of this content, please login or buy subscription here

Dilip Jeste, MD

Estelle and Edgar Levi Chair in Aging, Professor of Psychiatry and Neurosciences Chief, Division of Geriatric Psychiatry, UC San Diego

Dr. Jeste has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jeste has disclosed that risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole are not FDA-approved for the treatment of agitation or psychosis in dementia. Please see product inserts for full lists of approved indications.